Email This Article

Headlines & Perspectives
Why the Pros Are Passing on Encysive Pharma
By Adam Feuerstein
06/13/07 - 07:14 AM EDT
Shares have risen ahead of a huge FDA decision, but institutional holders haven't regained the faith.
Recipient's Email Address(es)
(Separate multiple addresses with a comma)
Your Email Address
Send a copy to myself
Your Message (optional)

Privacy Policy

The information entered on this page will not be used to send unsolicited email and will not be sold to a 3rd party.

Dow Jones S&P 500 NASDAQ 10-Year Note
10,243.04 1,093.24 2,151.74 34.88
Oil *
77.48
UP
16.10
UP
0.17
DOWN
2.32
UP
0.02
10 Yr
3.49%
SPDR Gold
108.28
+0.16%
+0.02%
-0.11%
+0.06%
Data delayed 20 minutes

Brokerage Partners